Lazard-backed SPACs aim to raise US$500m in IPOs
Bengaluru
TWO special purpose acquisition companies (SPACs) backed by investment bank Lazard are aiming to raise as much as US$500 million in initial public offerings, according to regulatory filings on Monday.
Lazard Healthcare Acquisition Corp I and Lazard Fintech Acquisition Corp I are looking to raise US$250 million each, saying they aim to merge with companies in the healthcare and fintech sectors, respectively.
In January, another SPAC backed by the investment bank said it aimed to raise US$500 million in a US IPO, with an eye on the healthcare, technology, energy transition, financial and consumer sectors.
SPACs are shell firms that have no business operations but are still listed. Their sole purpose is to use capital from an IPO to merge with a private firm, allowing them to go public with lesser regulatory scrutiny.
However, a surge in the number of such blank-cheque firms over the last year has prompted concerns of a bubble. The Defiance Next Gen SPAC Derived ETF, an exchange-traded fund (ETF) that tracks SPACs, fell 16 per cent from a year high in mid-February as of its last close.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
Lazard Healthcare Acquisition Corp I and Lazard Fintech Acquisition Corp I's units will be listed on Nasdaq under the symbols "LHCAU" and "LFTAU", respectively.
Goldman Sachs is the sole underwriter for both offerings. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services